rethinkPeptides Search
Menu
Study breakdown

How Milk Protein Processing Creates Different Peptides That Trigger the Same Hormone GLP-1 Drugs Target

evidence
The takeaway

Different casein manufacturing processes generate different peptides during digestion, with micellar casein producing a specific peptide (GPVRGPFPIIV) that stimulates natural GLP-1 release from gut cells.

GPVRGPFPIIV stimulates GLP-1

This specific 11-amino-acid peptide, found only in digested micellar casein concentrate, was confirmed to trigger GLP-1 release from gut cells — linking a dairy-derived peptide to the same hormonal pathway targeted by blockbuster diabetes and weight loss drugs.

What the researchers found

Different casein processing methods produce different peptide profiles during digestion and different levels of GLP-1 release. Micellar casein concentrate (MCC) had higher digestibility and induced greater GLP-1 secretion from enteroendocrine GLUTag cells than sodium caseinate mixed with whey protein isolate (SCN + WPI). A specific peptide — GPVRGPFPIIV — was identified only in MCC digesta and confirmed to stimulate GLP-1 release when chemically synthesized and tested.

Why it matters

GLP-1 is the hormone targeted by blockbuster drugs like semaglutide and tirzepatide. Finding that specific food-derived peptides from milk protein can naturally stimulate GLP-1 release suggests that the way dairy products are processed could influence their metabolic benefits. Identifying the exact peptide sequence (GPVRGPFPIIV) responsible provides a molecular basis for developing functional foods or supplements that promote natural GLP-1 release.

How the study worked

Micellar casein concentrate (MCC) and sodium caseinate with whey protein isolate (SCN + WPI) were subjected to standardized in vitro gastrointestinal digestion. Digestion patterns and released peptides were characterized. GLP-1 secretion was measured using enteroendocrine GLUTag cells exposed to the digested materials. Candidate GLP-1-releasing peptides were identified from the digesta, chemically synthesized, and individually tested for GLP-1-stimulating activity.

Who was studied

In vitro gastrointestinal digestion model and mouse enteroendocrine GLUTag cell line

What this study cannot tell us

All experiments were in vitro — the GLP-1-releasing effects have not been confirmed in animals or humans after oral consumption. In vitro digestion may not perfectly replicate the complexity of human gastrointestinal processing. The GLUTag cell model, while standard, may not fully represent the diversity of human enteroendocrine cells. The magnitude of GLP-1 release from the identified peptide relative to pharmacological GLP-1 RAs is not reported.

How to read the evidence

This is an in vitro study using standardized digestion models and cell culture assays. While the identification of a specific GLP-1-stimulating peptide sequence is rigorous, the complete absence of in vivo data means these findings are preliminary. The leap from cell culture GLP-1 release to meaningful physiological effects in humans requires substantial further validation.

When this study was published

Published in 2019, this study contributes to the growing field of food-derived bioactive peptides. The specific GPVRGPFPIIV peptide has potential for further development as a functional food ingredient.

The bigger picture

The discovery that food processing methods determine which bioactive peptides are released during digestion has significant implications for functional food design. In the era of GLP-1-based therapies for diabetes and obesity, the idea that dietary proteins could naturally stimulate GLP-1 release offers a complementary, food-based approach. Understanding exactly which peptide sequences are responsible enables the development of designer dairy products or supplements optimized for metabolic benefits.

Questions still open

  • Can consuming micellar casein concentrate produce meaningful GLP-1 increases in humans, and would this translate into blood sugar or appetite effects?
  • Could the identified GPVRGPFPIIV peptide be developed into a functional food ingredient or oral supplement for metabolic health?
  • How does the magnitude of GLP-1 release from food-derived peptides compare to pharmacological GLP-1 receptor agonists?

Common questions

Could drinking milk or eating cheese naturally boost GLP-1 levels?
This study suggests it's possible, but with an important caveat: the type of casein processing matters. Micellar casein concentrate (used in some protein supplements and dairy products) released GLP-1-stimulating peptides during digestion, while sodium caseinate (another common dairy ingredient) produced a different peptide profile with less GLP-1 activity. Regular milk consumption might have some effect, but it hasn't been confirmed in humans yet.
How does this compare to taking a GLP-1 drug like Ozempic?
The GLP-1 release from food-derived peptides would be much smaller and more transient than what pharmaceutical GLP-1 drugs produce. GLP-1 drugs are engineered to be highly potent and long-lasting (weekly injections). Dietary approaches would likely produce modest, meal-related GLP-1 increases — potentially useful for metabolic health maintenance rather than treating established diabetes or obesity.

Read the original research

Casein materials show different digestion patterns using an in vitro gastrointestinal model and different release of glucagon-like peptide-1 by enteroendocrine GLUTag cells.

Food chemistry, 277, 423-431

Citation

Komatsu, Yosuke; Wada, Yasuaki; Izumi, Hirohisa; Shimizu, Takashi; Takeda, Yasuhiro; Hira, Tohru; Hara, Hiroshi. (2019). Casein materials show different digestion patterns using an in vitro gastrointestinal model and different release of glucagon-like peptide-1 by enteroendocrine GLUTag cells.. Food chemistry, 277, 423-431. https://doi.org/10.1016/j.foodchem.2018.10.123